JP2019176880A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019176880A5 JP2019176880A5 JP2019131862A JP2019131862A JP2019176880A5 JP 2019176880 A5 JP2019176880 A5 JP 2019176880A5 JP 2019131862 A JP2019131862 A JP 2019131862A JP 2019131862 A JP2019131862 A JP 2019131862A JP 2019176880 A5 JP2019176880 A5 JP 2019176880A5
- Authority
- JP
- Japan
- Prior art keywords
- human
- several genes
- patients
- adaptive immune
- immune response
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12305975 | 2012-08-06 | ||
| EP12305975.0 | 2012-08-06 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015525857A Division JP6559566B2 (ja) | 2012-08-06 | 2013-08-05 | 癌患者をスクリーニングするための方法及びキット |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019176880A JP2019176880A (ja) | 2019-10-17 |
| JP2019176880A5 true JP2019176880A5 (https=) | 2021-05-06 |
| JP6995091B2 JP6995091B2 (ja) | 2022-01-14 |
Family
ID=46762994
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015525857A Active JP6559566B2 (ja) | 2012-08-06 | 2013-08-05 | 癌患者をスクリーニングするための方法及びキット |
| JP2019131862A Active JP6995091B2 (ja) | 2012-08-06 | 2019-07-17 | 癌患者をスクリーニングするための方法及びキット |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015525857A Active JP6559566B2 (ja) | 2012-08-06 | 2013-08-05 | 癌患者をスクリーニングするための方法及びキット |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20150218650A1 (https=) |
| EP (2) | EP3470531A1 (https=) |
| JP (2) | JP6559566B2 (https=) |
| AU (1) | AU2013301609B2 (https=) |
| CA (1) | CA2881389C (https=) |
| DK (1) | DK2880180T3 (https=) |
| ES (1) | ES2702722T3 (https=) |
| LT (1) | LT2880180T (https=) |
| PL (1) | PL2880180T3 (https=) |
| PT (1) | PT2880180T (https=) |
| SG (1) | SG11201500922RA (https=) |
| TR (1) | TR201819211T4 (https=) |
| WO (1) | WO2014023706A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| RU2020127099A (ru) * | 2014-08-19 | 2020-09-02 | Нэшнл Юниверсити Корпорейшн Окаяма Юниверсити | Способ улучшения функции иммунных клеток и оценки мультифункциональности иммунных клеток |
| JP2018503373A (ja) * | 2014-12-30 | 2018-02-08 | ジェネンテック， インコーポレイテッド | がんの予後診断及び治療のための方法及び組成物 |
| US20190309369A1 (en) * | 2016-05-09 | 2019-10-10 | Inserm (Institute National De La Sante Et De La Recherche Medicale) | Methods for classifying patients with a solid cancer |
| CN110546277B (zh) | 2017-03-01 | 2024-06-11 | 豪夫迈·罗氏有限公司 | 用于癌症的诊断和治疗方法 |
| US11311945B2 (en) | 2018-03-22 | 2022-04-26 | Sumitomo Electric Hardmetal Corp. | Surface-coated cutting tool and method for manufacturing same |
| US20210381058A1 (en) * | 2018-10-01 | 2021-12-09 | Nantomics, Llc | Evidence based selection of patients for clinical trials using histopathology |
| CN114072676B (zh) | 2019-06-03 | 2024-07-12 | 法国国家卫生及研究医学协会 | 调节治疗方案的方法 |
| CA3151629A1 (en) | 2019-11-07 | 2021-05-14 | Laura E. BENJAMIN | Classification of tumor microenvironments |
| GB202007099D0 (en) | 2020-05-14 | 2020-07-01 | Kymab Ltd | Tumour biomarkers for immunotherapy |
| CN115997123A (zh) | 2020-06-30 | 2023-04-21 | 国家医疗保健研究所 | 用于预测实体癌患者在术前辅助治疗后复发和/或死亡风险的方法 |
| JP7741831B2 (ja) | 2020-06-30 | 2025-09-18 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 術前補助療法及び根治手術後の固形がんを患っている患者の再発及び／又は死亡のリスクを予測するための方法 |
| US20250035635A1 (en) | 2022-03-17 | 2025-01-30 | Institut National De La Sante Et De La Recherche Medicale | Methods for predicting response to an immunotherapeutic treatment in a patient with a cancer |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4888278A (en) | 1985-10-22 | 1989-12-19 | University Of Massachusetts Medical Center | In-situ hybridization to detect nucleic acid sequences in morphologically intact cells |
| US6280929B1 (en) | 1986-01-16 | 2001-08-28 | The Regents Of The University Of California | Method of detecting genetic translocations identified with chromosomal abnormalities |
| US5447841A (en) | 1986-01-16 | 1995-09-05 | The Regents Of The Univ. Of California | Methods for chromosome-specific staining |
| US5427932A (en) | 1991-04-09 | 1995-06-27 | Reagents Of The University Of California | Repeat sequence chromosome specific nucleic acid probes and methods of preparing and using |
| US5472842A (en) | 1993-10-06 | 1995-12-05 | The Regents Of The University Of California | Detection of amplified or deleted chromosomal regions |
| US6942970B2 (en) | 2000-09-14 | 2005-09-13 | Zymed Laboratories, Inc. | Identifying subjects suitable for topoisomerase II inhibitor treatment |
| JP2002363169A (ja) * | 2001-06-08 | 2002-12-18 | Fujiyakuhin Co Ltd | 抗腫瘍活性を有する複素環化合物 |
| EP2157524A3 (en) * | 2003-09-03 | 2010-12-08 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Methods for identifying, diagnosing, and predicting survival of lymphomas |
| US20110152115A1 (en) * | 2003-09-03 | 2011-06-23 | The United States of America, as represented by the Secretary, Department of Health and | Methods for identifying, diagnosing, and predicting survival of lymphomas |
| US20060246523A1 (en) | 2005-04-28 | 2006-11-02 | Christopher Bieniarz | Antibody conjugates |
| CA2606018A1 (en) | 2005-04-28 | 2006-11-02 | Ventana Medical Systems, Inc. | Nanoparticle conjugates |
| EP1777523A1 (en) | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
| DK2963011T3 (en) | 2005-11-23 | 2018-08-06 | Ventana Med Syst Inc | MOLECULAR CONJUGATE |
| US20110070582A1 (en) * | 2008-11-03 | 2011-03-24 | Source Precision Medicine, Inc. d/b/d Source MDX | Gene Expression Profiling for Predicting the Response to Immunotherapy and/or the Survivability of Melanoma Subjects |
| PT2619576T (pt) * | 2010-09-24 | 2020-09-14 | Niels Grabe | Meios e métodos para a previsão de resposta ao tratamento de um paciente com cancro |
| DK3141617T3 (en) * | 2011-01-11 | 2019-02-25 | Inst Nat Sante Rech Med | PROCEDURE FOR PREVENTING THE CANCER OF A CANCER ON A PATIENT BY ANALYZING GENEPRESSION |
-
2013
- 2013-08-05 LT LTEP13745117.5T patent/LT2880180T/lt unknown
- 2013-08-05 TR TR2018/19211T patent/TR201819211T4/tr unknown
- 2013-08-05 PT PT13745117T patent/PT2880180T/pt unknown
- 2013-08-05 ES ES13745117T patent/ES2702722T3/es active Active
- 2013-08-05 CA CA2881389A patent/CA2881389C/en active Active
- 2013-08-05 EP EP18196198.8A patent/EP3470531A1/en not_active Withdrawn
- 2013-08-05 EP EP13745117.5A patent/EP2880180B1/en active Active
- 2013-08-05 AU AU2013301609A patent/AU2013301609B2/en not_active Ceased
- 2013-08-05 WO PCT/EP2013/066425 patent/WO2014023706A1/en not_active Ceased
- 2013-08-05 US US14/420,053 patent/US20150218650A1/en not_active Abandoned
- 2013-08-05 PL PL13745117T patent/PL2880180T3/pl unknown
- 2013-08-05 DK DK13745117.5T patent/DK2880180T3/en active
- 2013-08-05 JP JP2015525857A patent/JP6559566B2/ja active Active
- 2013-08-05 SG SG11201500922RA patent/SG11201500922RA/en unknown
-
2019
- 2019-07-17 JP JP2019131862A patent/JP6995091B2/ja active Active
-
2020
- 2020-06-09 US US16/896,736 patent/US20200299784A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019176880A5 (https=) | ||
| Kim et al. | Updates on immunotherapy and immune landscape in renal clear cell carcinoma | |
| Meng et al. | Using ESTIMATE algorithm to establish an 8-mRNA signature prognosis prediction system and identify immunocyte infiltration-related genes in Pancreatic adenocarcinoma | |
| Riva et al. | Multiparametric flow cytometry for MRD monitoring in hematologic malignancies: clinical applications and new challenges | |
| Guo et al. | TOX correlates with prognosis, immune infiltration, and T cells exhaustion in lung adenocarcinoma | |
| Dama et al. | Biomarkers and lung cancer early detection: state of the art | |
| Gasch et al. | Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer | |
| Johnson et al. | Phase II study of dasatinib in patients with advanced non–small-cell lung cancer | |
| Zhang et al. | CXCL5 overexpression predicts a poor prognosis in pancreatic ductal adenocarcinoma and is correlated with immune cell infiltration | |
| Lin et al. | Prognostic impact of circulating monocytes and lymphocyte-to-monocyte ratio on previously untreated metastatic non-small cell lung cancer patients receiving platinum-based doublet | |
| AU2015230677A1 (en) | Determining cancer agressiveness, prognosis and responsiveness to treatment | |
| JP2015530877A5 (https=) | ||
| WO2015138769A1 (en) | Methods and compositions for assessing patients with non-small cell lung cancer | |
| Kawashima et al. | Double-expressor lymphoma is associated with poor outcomes after allogeneic hematopoietic cell transplantation | |
| Anjomshoaa et al. | Slow proliferation as a biological feature of colorectal cancer metastasis | |
| Fan et al. | Serum pre-albumin predicts the clinical outcome in metastatic castration-resistant prostate cancer patients treated with abiraterone | |
| Makise et al. | Squamous differentiation and prognosis in upper urinary tract urothelial carcinoma | |
| Szczepanski et al. | Clinical evaluation of the pancreatic cancer microenvironment: opportunities and challenges | |
| WO2024086617A3 (en) | Ph-dependent anti-cd3 antibodies and methods relating thereto | |
| He et al. | Integrative analysis of Ewing’s sarcoma reveals that the MIF-CD74 axis is a target for immunotherapy | |
| Yao et al. | Breast cancer patients: who would benefit from neoadjuvant chemotherapies? | |
| Haist et al. | Response to primary chemoradiotherapy of locally advanced oropharyngeal carcinoma is determined by the degree of cytotoxic T cell infiltration within tumor cell aggregates | |
| Ettorre et al. | Personalized treatment in ovarian cancer: A review of disease monitoring, biomarker expression, and targeted treatments for advanced, recurrent ovarian cancers | |
| Moes-Sosnowska et al. | FGFR1–4 RNA-Based Gene Alteration and Expression Analysis in Squamous Non-Small Cell Lung Cancer | |
| Bai et al. | Stroma-infiltrating T cell spatiotypes define immunotherapy outcomes in adolescent and young adult patients with melanoma |